GHB Does Not Help with Manic Symptoms and May Worsen Them
GHB (gamma-hydroxybutyrate) is not an appropriate treatment for manic symptoms and should be avoided in patients with bipolar disorder. In fact, evidence demonstrates that GHB can induce psychosis and worsen psychiatric symptoms in patients with mood disorders.
Evidence Against GHB for Mania
Direct Contraindication from Clinical Evidence
A case report specifically documents a patient with bipolar disorder (on valproate for mood stabilization) who developed recurrent convulsive seizures and psychosis after switching from disulfiram to GHB for alcohol dependence treatment 1. The seizures were resistant to standard benzodiazepine treatment, and both seizures and psychiatric symptoms only resolved after GHB discontinuation. This demonstrates that GHB can trigger severe psychiatric decompensation in patients with underlying bipolar disorder.
Established Treatment Guidelines
The American Academy of Child and Adolescent Psychiatry practice parameters clearly outline that standard pharmacotherapy for mania includes lithium, valproate, and/or atypical antipsychotic agents 2. GHB is conspicuously absent from any treatment recommendations for bipolar disorder or manic symptoms. The guidelines emphasize that treatment should begin with FDA-approved agents for bipolar disorder, which include:
- Lithium (approved for acute mania and maintenance)
- Atypical antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone)
- Valproate for acute mania
- Lamotrigine for maintenance therapy
Why GHB Is Problematic
Mechanism of action concerns: GHB acts as a GHB/GABA-B receptor agonist and modulates dopaminergic transmission 1, 3. While it can produce euphoria and mood enhancement in healthy individuals 4, 5, these effects are fundamentally different from mood stabilization. The drug's ability to increase dopamine levels and alter GABAergic transmission can destabilize mood in patients with bipolar disorder, potentially triggering manic episodes or psychosis.
Abuse potential and safety profile: GHB is classified as a drug of abuse with significant risks including:
- Severe withdrawal syndrome with delirium, hemodynamic instability, and rhabdomyolysis 6
- Steep concentration-effect curve leading to frequent overdoses 3
- Risk of respiratory depression, coma, and death 3
- Potential for addiction and misuse 7
Clinical Bottom Line
Use evidence-based antimanic agents: For acute mania, initiate treatment with lithium, valproate, or an atypical antipsychotic based on clinical presentation, side effect profile, and patient history 2. Benzodiazepines may be used adjunctively for acute agitation and sleep disturbance, though they can cause disinhibition in younger patients 2.
Avoid GHB entirely in bipolar patients: Even when GHB is used for its approved indication (narcolepsy treatment as sodium oxybate) 7, there is no evidence supporting its use in mania, and case evidence demonstrates it can precipitate psychiatric crises in patients with mood disorders 1.
Common pitfall: Do not confuse GHB's euphoric effects in healthy individuals with therapeutic mood stabilization. The subjective "mood enhancement" reported by recreational users 4, 8, 5 represents disinhibition and altered consciousness, not the controlled mood regulation needed in bipolar disorder treatment.